[go: up one dir, main page]

AR073629A1 - BENZODIOXAN ANALOGS MODULATORS OF ADRENERGIC RECEPTORS ALFA 2C, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT RESPIRATORY, ALLERGIC, CARDIAC, PARKINSON AND / OR ALZHEIMER DISEASES, BETWEEN OTHERS - Google Patents

BENZODIOXAN ANALOGS MODULATORS OF ADRENERGIC RECEPTORS ALFA 2C, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT RESPIRATORY, ALLERGIC, CARDIAC, PARKINSON AND / OR ALZHEIMER DISEASES, BETWEEN OTHERS

Info

Publication number
AR073629A1
AR073629A1 ARP090103841A ARP090103841A AR073629A1 AR 073629 A1 AR073629 A1 AR 073629A1 AR P090103841 A ARP090103841 A AR P090103841A AR P090103841 A ARP090103841 A AR P090103841A AR 073629 A1 AR073629 A1 AR 073629A1
Authority
AR
Argentina
Prior art keywords
group
groups
heterocyclyl
optionally substituted
alkyl
Prior art date
Application number
ARP090103841A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR073629A1 publication Critical patent/AR073629A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto representado por la formula (1) o una sal farmacéuticamente aceptable del mismo donde J1, J2, J3 y J4 son independientemente -N-, -N(O)-, o -C(R2)-; X es -C(R6)(R6')-, -N(R6')-, -O-, o -S-; W es -N(R14)-, -O- o -S-; - - - - - - es un enlace simple o doble, con la condicion de que no pueda haber dos enlaces dobles continuos; R1 es un anillo seleccionado del grupo constituido por cicloalquilo, cicloalquenilo, arilo, heterociclilo, heterociclenilo, y heteroarilo, cada uno de los cuales está opcionalmente sustituido con por lo menos un R12; R2 está ausente o independientemente seleccionado del grupo que consiste en H, halo, -CN, -NO2, -OH, -SF5, -OSF5, -S(O)pR7, -NR7R7', -[C(Ra)(Rb)]qYR7', -[C(Ra)(Rb)]qN(R7)YR7', -[C(Ra)(Rb)]qN(R7)CN, -[C(Ra)(Rb)]qO)YR7', -(CH2)qON=CR7R7', y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo sustituidos con por lo menos un R5; Y está seleccionado del grupo que consiste en un enlace, -C(=O)-, -C(=O)NR7-, -C(=O)O-, -C(=O)N(Rc)-O-, -C(=NR7)-, -C(=NOR7)-, -C(=NR7)NR7-, -C(=NR7)NR7O-, -C(=N-CN)-, -S(O)p-, -SO2NR7-, y -C(=S)NR7-; donde Ra y Rb son seleccionados en forma independiente del grupo constituido por H, alquilo, alcoxi, y halo, y Rc es H o alquilo; R3 es independientemente seleccionado del grupo conformado por H, -OH, halo, -CN, -NO2, -S(O)pR7, -NR7R7', -S(O)pNR7R7', y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo opcionalmente sustituidos con por lo menos un R5; R3' es independientemente seleccionado del grupo conformado por H, OH, halo, y alquilo, y alcoxi; o R3 y R3' pueden formar, juntos (=O), con la condicion de que, cuando n > 1, no haya más de 1 grupo (=O); R4 es independientemente seleccionado del grupo conformado por H, -OH, halo, -CN, -NO2, -SF5, -OSF5, -S(O)pR7, -NR7R7', -S(O)pNR7R7', -C(O)-R7, -C(O)-OR7, -C(O)-NR7, y (=O), y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo opcionalmente sustituido con por lo menos uno R5; R5 es independientemente seleccionado del grupo conformado por H, halo, - OH, -CN, -NO2, -SF5, -OSF5, -NR7R7', y -S(O)pR7, y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo, cada uno de los cuales está opcionalmente sustituido con por lo menos uno (preferentemente de 1 a 5, más preferentemente de 1 a 3) sustituyentes halo, -OH, -CN, -NO2, -NR7R7', y S(O)pR7 y/o 1 o 2 grupos (=O); R6 es independientemente seleccionado del grupo conformado por H, -OH, halo, -CN, -NO2, -SF5, -OSF5, -S(O)pR7, -NR7R7', -S(O)pNR7R7', -C(O)-R10, -C(O)-OR10 y -C(O)-N(R7)R10, y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo, cada uno de los cuales está opcionalmente sustituido con por lo menos uno de los sustituyentes halo, -OH, -CN, -NO2, -NR7R7', y -S(O)pR7 y/o 1 o 2 grupos (=O), y -C(=O)R7, -C(=O)OR7, -C(=O)NR7R7', -SO2R7 y -SO2NR7R7'; R6' es independientemente seleccionado del grupo conformado por H, -S(O)pR7, -S(O)NR7R7', -C(O)-R10, -C(O)-OR10, -C(O)-N(R7)R10 y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo, cada uno de los cuales está opcionalmente sustituido con por lo menos uno de los sustituyentes halo, -OH, -CN, -NO2, -NR7R7', y -S(O)pR7 y/o 1 o 2 grupos (=O), Y -C(=O)R7, -C(=O)OR7, -C(=O)NR7R7', -SO2R7 y -SO2NR7R7'; o cuando X es -C(R6)(R6'), R6 y R6' juntos pueden formar (=O); R7 es independientemente seleccionado de! grupo conformado por H y grupos alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, cicloclenilo, ciclociclenilalquilo, arilo, arilalquilo, heterociclilo, heterociclilalquilo, hetrociclenilo, heterociclenilalquilo, heteroarilo, y heteroarilalquilo, cada uno de los cuales está opcionalmente sustituido una o más veces con R12; R7' es independientemente seleccionado del grupo conformado por H y grupos alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, cicloclenilo, cicloclenilalquilo, arilo, arilalquilo, heterociclilo, heterociclilalquilo, heterociclenilo, heterociclenilalquilo, heteroarilo, y heteroarilalquilo, cada uno de los cuales está opcionalmente sustituido una o más veces con R12; o a) cuando una variable es -NR7R7', -C(O)NR7R7' o -SO2NR7R7', R7 y R7' conjuntamente con el átomo de nitrogeno al cual están unidos forman independientemente un anillo heterociclilo, heterociclenilo o heteroarilo de 3 a 8 miembros, que tiene además del átomo N, 1 o 2 heteroátomos adicionales independientemente seleccionados del grupo que consiste en O, N, -N(R9)- y S, donde dichos anillos están opcionalmente sustituidos con 1 a 5 restos R12 independientemente seleccionados y/o 1 o 2 grupos (=O), o b) cuando una variable es -(CH2)qON=CR7R7', R7 y R7' junto con el átomo de carbono al cual están unidos forman de manera independiente un anillo de cicloalquilo, cicloalquenilo, arilo, heterociclilo, heterociclenilo o heteroarilo de 3 a 8 miembros, donde dichos anillos heterociclilo, heterociclenilo o heteroarilo tienen 1 a 3 heteroátomos que están independientemente seleccionados del grupo que consiste en O, N, -N(R9)- y S, donde dichos anillos están opcionalmente sustituidos con 1 a 5 restos R12 independientemente seleccionados y/o 1 o 2 grupos (=O); R8 es independientemente seleccionado del grupo conformado por H, -OH, halo, -CN, -NO2, -S(O)pR7, -NR7R7', -S(O)pNR7R7' y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo opcionalmente sustituido con por lo menos un R5; R9 es independientemente seleccionado del grupo conformado por H, -C(O)-R10, -C(O)-OR10, y -S(O)p-R10 y grupos alquilo, alquenilo, alquinilo, cicloalquilo, arilo, arilalquilo, heteroarilo, y heteroarilalquilo, cada uno de los cuales está opcionalmente sustituido con por lo menos un sustituyente halo, -OH, -CN, -NO2, -N(R11)2, y -S(O)pR11 y/o 1 o 2 grupos (=O); y R10 es independientemente seleccionado del grupo constituido por H, y grupos alquilo, alquenilo, alquinilo, cicloalquilo, arilo, arilalquilo, heteroarilo, y heteroarilalquilo, cada uno de los cuales está opcionalmente sustituido con por lo menos uno de los sustituyentes halo, -OH, -CN, -NO2, -N(R11)2, y -S(O)pR11 y/o 1 o 2 (=O); R11 es un resto independientemente seleccionado del grupo constituido por H y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo, cada uno de los cuales está opcionalmente sustituido con por lo menos un sustituyente seleccionado del grupo constituido por halo, -OH, -CN, - NO2, -N(R11')2, y -S(O)pR11' y/o 1 o 2 grupos (=O); R11' es independientemente seleccionado del grupo conformado por H, alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R12 es independientemente seleccionado del grupo que consiste en H, halo, -OH, -CN, -NO2, -SF5, -OSF5, -N(R11)2, -C(O)-OR13, -C(O)-R13, -N(R13)-C(O)-R13, -N(R13)-C(O)2-R13, -C(O)-N(R11)2, -N(R14)-S(O)2-R11, -S(O)2-N(R11)2 y -S(O)pR11 y/o 1 o 2 grupos (=O), y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalquenilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroariloxi, heteroarilalquilo, heterociclilo, heterociclenilo, heterocicleniloxi, heterociclilalquilo, heterociclenilalquilo, arilalcoxi, heteroarilalcoxi, heterocicliIalcoxi, y heterociclenilalcoxi, cada uno de los cuales está opcionalmente sustituido, a su vez, con al menos un sustituyente seleccionado del grupo que consiste en H, alquilo, haloalquilo, halo, -OH, alcoxi opcionalmente sustituido , ariloxi opcionalmente sustituido, cicloalcoxi opcionalmente sustituido , heteroalcoxi opcionalmente sustituido, heterocicleniloxi opcionalmente sustituido, -CN, -NO2, -N(R11)2, y -S(O)pR11 y/o 1 o 2 grupos (=O ), donde dichos alcoxi opcionalmente sustituido, ariloxi, cicloalcoxi opcionalmente sustituido, heteroariloxi opcionalmente sustituido y heterocicleniloxi en caso de estar sustituidos, están sustituidos una o más veces (preferentemente de 1 a 5, más preferentemente de 1 a 3) con R11; R13 es independientemente H, alquilo, o arilo; R14 es seleccionado del grupo constituido por H, -C(O)-R10, -C(O)-OR10, -C(=O)-N(R7)(R7'), y -S(O)p-R10, -SO2-NR7R7' y grupos alquilo, alcoxi, alquenilo, alqueniloxi, alquinilo, cicloalquilo, cicloalcoxi, arilo, ariloxi, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo, cada uno de los cuales está opcionalmente sustituido con por lo menos uno de los sustituyentes halo, -OH, -CN, -NO2, -NR7R7', y -S(O)pR7 y/o 1 o 2 grupos (=O) y -C(=O)R7, -C(=O)OR7, -C(=O)NR7R7', -SO2R7 y -SO2NR7R7'; q es independientemente un numero entero de 0-10; n es 1 o 2; m es un numero entero de 1-3; p es independientemente un numero entero de 0-2; y w es independientemente un numero entero de 0-6, con la condicion de que, cuando X es O y W es NH, m es 1 y n es 1, luego R1 no puede ser fenilo.Claim 1: A compound represented by formula (1) or a pharmaceutically acceptable salt thereof wherein J1, J2, J3 and J4 are independently -N-, -N (O) -, or -C (R2) -; X is -C (R6) (R6 ') -, -N (R6') -, -O-, or -S-; W is -N (R14) -, -O- or -S-; - - - - - - is a single or double bond, with the proviso that there cannot be two continuous double bonds; R1 is a ring selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heterocyclynyl, and heteroaryl, each of which is optionally substituted with at least one R12; R2 is absent or independently selected from the group consisting of H, halo, -CN, -NO2, -OH, -SF5, -OSF5, -S (O) pR7, -NR7R7 ', - [C (Ra) (Rb) ] qYR7 ', - [C (Ra) (Rb)] qN (R7) YR7', - [C (Ra) (Rb)] qN (R7) CN, - [C (Ra) (Rb)] qO) YR7 ', - (CH2) qON = CR7R7', and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl groups substituted with at least one R5; Y is selected from the group consisting of a link, -C (= O) -, -C (= O) NR7-, -C (= O) O-, -C (= O) N (Rc) -O- , -C (= NR7) -, -C (= NOR7) -, -C (= NR7) NR7-, -C (= NR7) NR7O-, -C (= N-CN) -, -S (O) p-, -SO2NR7-, and -C (= S) NR7-; where Ra and Rb are independently selected from the group consisting of H, alkyl, alkoxy, and halo, and Rc is H or alkyl; R3 is independently selected from the group consisting of H, -OH, halo, -CN, -NO2, -S (O) pR7, -NR7R7 ', -S (O) pNR7R7', and alkyl, alkoxy, alkenyl, alkenyloxy groups, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl optionally substituted with at least one R5; R3 'is independently selected from the group consisting of H, OH, halo, and alkyl, and alkoxy; or R3 and R3 'can form, together (= O), with the proviso that, when n> 1, there is no more than 1 group (= O); R4 is independently selected from the group consisting of H, -OH, halo, -CN, -NO2, -SF5, -OSF5, -S (O) pR7, -NR7R7 ', -S (O) pNR7R7', -C (O ) -R7, -C (O) -OR7, -C (O) -NR7, and (= O), and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl groups, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl optionally substituted with at least one R5; R5 is independently selected from the group consisting of H, halo, - OH, -CN, -NO2, -SF5, -OSF5, -NR7R7 ', and -S (O) pR7, and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl groups , cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, each of which is optionally substituted with at least one (preferably 1 to 5, more preferably 1 to 3) halo substituents, -OH, -CN, -NO2, -NR7R7 ', and S (O) pR7 and / or 1 or 2 groups (= O); R6 is independently selected from the group consisting of H, -OH, halo, -CN, -NO2, -SF5, -OSF5, -S (O) pR7, -NR7R7 ', -S (O) pNR7R7', -C (O ) -R10, -C (O) -OR10 and -C (O) -N (R7) R10, and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl groups, heterocyclyl, and heterocyclylalkyl, each of which is optionally substituted with at least one of the halo substituents, -OH, -CN, -NO2, -NR7R7 ', and -S (O) pR7 and / or 1 or 2 groups (= O), and -C (= O) R7, -C (= O) OR7, -C (= O) NR7R7 ', -SO2R7 and -SO2NR7R7'; R6 'is independently selected from the group consisting of H, -S (O) pR7, -S (O) NR7R7', -C (O) -R10, -C (O) -OR10, -C (O) -N ( R7) R10 and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl groups, each of which is optionally substituted with at least one of the substituents halo, -OH, -CN, -NO2, -NR7R7 ', and -S (O) pR7 and / or 1 or 2 groups (= O), Y -C (= O) R7, -C (= O) OR7 , -C (= O) NR7R7 ', -SO2R7 and -SO2NR7R7'; or when X is -C (R6) (R6 '), R6 and R6' together can form (= O); R7 is independently selected from! group consisting of H and alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloclenyl, cyclocyclylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclynyl, heterocyclylalkyl, heteroaryl, and heteroaryl groups, each of which is optionally substituted with one or more times. R12; R7 'is independently selected from the group consisting of H and alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloclenyl, cycloclenylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl groups, and optionally each of which is one of substituted one or more times with R12; or) when a variable is -NR7R7 ', -C (O) NR7R7' or -SO2NR7R7 ', R7 and R7' together with the nitrogen atom to which they are attached independently form a 3- to 8-membered heterocyclyl, heterocyclyl or heteroaryl ring , which in addition to the atom N, 1 or 2 additional heteroatoms independently selected from the group consisting of O, N, -N (R9) - and S, wherein said rings are optionally substituted with 1 to 5 independently selected R12 moieties and / or 1 or 2 groups (= O), or b) when a variable is - (CH2) qON = CR7R7 ', R7 and R7' together with the carbon atom to which they are attached independently form a cycloalkyl, cycloalkenyl, aryl ring , 3 to 8-membered heterocyclyl, heterocyclyl or heteroaryl, wherein said heterocyclyl, heterocyclyl or heteroaryl rings have 1 to 3 heteroatoms that are independently selected from the group consisting of O, N, -N (R9) - and S, wherein said rings are optionally substituted with 1 to 5 independently selected R12 residues and / or 1 or 2 groups (= O); R8 is independently selected from the group consisting of H, -OH, halo, -CN, -NO2, -S (O) pR7, -NR7R7 ', -S (O) pNR7R7' and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl groups , cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclyl alkyl optionally substituted with at least one R5; R9 is independently selected from the group consisting of H, -C (O) -R10, -C (O) -OR10, and -S (O) p-R10 and alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl groups , and heteroarylalkyl, each of which is optionally substituted with at least one halo substituent, -OH, -CN, -NO2, -N (R11) 2, and -S (O) pR11 and / or 1 or 2 groups (= O); and R10 is independently selected from the group consisting of H, and alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl groups, each of which is optionally substituted with at least one of the halo substituents, -OH , -CN, -NO2, -N (R11) 2, and -S (O) pR11 and / or 1 or 2 (= O); R 11 is a moiety independently selected from the group consisting of H and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl groups, each of which is optionally substituted with at least one substituent selected from the group consisting of halo, -OH, -CN, -NO2, -N (R11 ') 2, and -S (O) pR11' and / or 1 or 2 groups (= O); R 11 'is independently selected from the group consisting of H, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R12 is independently selected from the group consisting of H, halo, -OH, -CN, -NO2, -SF5, -OSF5, -N (R11) 2, -C (O) -OR13, -C (O) -R13 , -N (R13) -C (O) -R13, -N (R13) -C (O) 2-R13, -C (O) -N (R11) 2, -N (R14) -S (O) 2-R11, -S (O) 2-N (R11) 2 and -S (O) pR11 and / or 1 or 2 groups (= O), and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkenyl groups , cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroaryloxy, heteroarylalkyl, heterocyclyl, heterocyclynyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkyl, arylalkoxy, heteroarylalkoxy, heterocyclyl at least one-and-one, at least one-and-one heterocycle, a substituent selected from the group consisting of H, alkyl, haloalkyl, halo, -OH, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted cycloalkoxy, optionally substituted heteroalkoxy, optionally substituted heterocyclynyloxy, -CN, -NO2, -N (R11) 2, and -S (O) pR11 and / or 1 or 2 groups (= O), wherein said optionally substituted alkoxy, aryloxy, optionally substituted cycloalkoxy, optionally substituted heteroaryloxy and heterocyclyloxy if substituted, are substituted one or more times (preferably 1 to 5, more preferably 1 a 3) with R11; R13 is independently H, alkyl, or aryl; R14 is selected from the group consisting of H, -C (O) -R10, -C (O) -OR10, -C (= O) -N (R7) (R7 '), and -S (O) p-R10 , -SO2-NR7R7 'and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl groups, each of which is optionally substituted with at least one of the halo substituents, -OH, -CN, -NO2, -NR7R7 ', and -S (O) pR7 and / or 1 or 2 groups (= O) and -C (= O) R7, -C (= O ) OR7, -C (= O) NR7R7 ', -SO2R7 and -SO2NR7R7'; q is independently an integer from 0-10; n is 1 or 2; m is an integer of 1-3; p is independently an integer from 0-2; and w is independently an integer from 0-6, with the proviso that, when X is O and W is NH, m is 1 and n is 1, then R1 cannot be phenyl.

ARP090103841A 2008-10-07 2009-10-06 BENZODIOXAN ANALOGS MODULATORS OF ADRENERGIC RECEPTORS ALFA 2C, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT RESPIRATORY, ALLERGIC, CARDIAC, PARKINSON AND / OR ALZHEIMER DISEASES, BETWEEN OTHERS AR073629A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10340108P 2008-10-07 2008-10-07

Publications (1)

Publication Number Publication Date
AR073629A1 true AR073629A1 (en) 2010-11-17

Family

ID=41328801

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103841A AR073629A1 (en) 2008-10-07 2009-10-06 BENZODIOXAN ANALOGS MODULATORS OF ADRENERGIC RECEPTORS ALFA 2C, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT RESPIRATORY, ALLERGIC, CARDIAC, PARKINSON AND / OR ALZHEIMER DISEASES, BETWEEN OTHERS

Country Status (3)

Country Link
AR (1) AR073629A1 (en)
TW (1) TW201026688A (en)
WO (1) WO2010042477A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58651B1 (en) * 2014-10-15 2019-05-31 Boehringer Ingelheim Int Aldosterone synthase inhibitors
JP7530384B2 (en) 2019-05-01 2024-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング (R)-(2-Methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
AR127948A1 (en) 2021-12-14 2024-03-13 Boehringer Ingelheim Int ALDOSTERONE SYNTHASE INHIBITORS TO TREAT CHRONIC KIDNEY DISEASE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478069T1 (en) * 2005-08-25 2010-09-15 Schering Corp 3,4-DIHYDRO-2H-BENZOÄ1,4ÜOXAZINE AND 3,4-DIHYDRO-2H-BENZOÄ1,4ÜTHIAZINE COMPOUNDS AS ALPHA2C ADRENORECEPTOR ANTAGONISTS
WO2008100459A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists

Also Published As

Publication number Publication date
TW201026688A (en) 2010-07-16
WO2010042477A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
MX2024004788A (en) Neuroactive steroids and their methods of use.
AR065311A1 (en) ALFA2C ADRENORECEPTOR AGONISTS FUNCTIONALLY SELECTIVE AND PHARMACEUTICAL COMPOSITION
AR073630A1 (en) ESPIROAMINOOXAZOLINE ANALOGS AS MODULATORS OF ALFA2C ADRENERGIC RECEPTORS
AR083367A1 (en) QUINAZOLINONE TYPE COMPOUNDS AS CRTH ANTAGONISTS
JP2016540742A5 (en)
AR065307A1 (en) ALFA2C ADRENORECEPTORS AGONISTS FUNCTIONALLY SELECTIVE AND PHARMACEUTICAL COMPOSITION
AR073993A1 (en) COMPOUND OF PIRAZOLILAMINOPIRIDINA, PHARMACEUTICALLY ACCEPTABLE COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICATION TO TREAT CANCER
JP2019510082A5 (en)
AR057771A1 (en) ALFA2C ADRENORECEPTORS AGONISTS
AR061438A1 (en) DERIVATIVES OF ENTACAPONE
AR056043A1 (en) ALFA2C FUNCTIONALLY SELECTIVE ADRENERGIC RECEIVERS AGONISTS
JP2014521688A5 (en)
AR065310A1 (en) ALFA2C ADRENORECEPTORS AGONISTS
PL402388A1 (en) Pyrimidine derivative, its use and pharmaceutical composition containing it
AR113918A1 (en) ANTIVIRAL AGENTS AGAINST HEPATITIS B
AR029717A1 (en) DERIVATIVES OF THE PRO-PHARMACO OF 4-PHENYL-PYRIDINE
AR106041A1 (en) MODULATORS OF THE CORE PROTEIN OF HEPATITIS B
AR060533A1 (en) CONDENSED HETEROCICLIC FENIL AMIDO COMPOUNDS
RU2010116253A (en) N-HYDROXYSULFULAMAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY APPLICABLE NITROXYL DONORS
PE20212253A1 (en) 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATATED CARDIOMYOPATHY (DCM)
RU2010151142A (en) SUBSTITUTED QUINAZOLES
JP2020507589A5 (en)
JP2017538689A5 (en)
AR112900A1 (en) COMPOUND DERIVED FROM PIRAZOLE AND USE OF IT
FI3518982T3 (en) Controlled-release pth compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal